Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: Fact or fiction?

CHEN-HUA LIUJIA-HORNG KAO2021-09-042021-09-0420162218-676Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-84991765428&doi=10.21037%2ftcr.2016.07.32&partnerID=40&md5=36dc227ce99cd6449c1feda9e7bfed9chttps://scholars.lib.ntu.edu.tw/handle/123456789/581924[SDGs]SDG3ADAM10 endopeptidase; antivirus agent; beta catenin; cyclin G1; glycogen synthase kinase 3beta; host factor; interferon; microRNA 122; antiviral therapy; cancer recurrence; chemoembolization; chronic hepatitis C; cytokine response; Editorial; health care quality; human; liver cell carcinoma; liver cirrhosis; liver fibrosis; prevalence; protein blood level; recurrence risk; retrospective study; treatment response; tumor growth; tumor recurrenceHepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: Fact or fiction?editorial10.21037/tcr.2016.07.322-s2.0-84991765428